Abstract
Twenty-eight patients with advanced squamous carcinoma of the uterine cervix received cisplatin, bleomycin, and mitomycin after failure of surgery and/or irradiation to control disease. Six patients (21%) achieved responses (two complete; four partial), ranging from 3 to 7+ months. Toxicity was acceptable for most patients; however, dose reduction because of myelosuppression was frequently required. Bleomycin was delivered by continuous iv infusion, and no significant pulmonary toxicity was observed. Although this combination of drugs has activity in advanced squamous carcinoma of the uterine cervix, the addition of cisplatin to bleomycin and mitomycin did not significantly increase the clinical response rate.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bleomycin / administration & dosage
-
Carcinoma, Squamous Cell / drug therapy*
-
Carcinoma, Squamous Cell / secondary
-
Cisplatin / administration & dosage
-
Drug Evaluation
-
Female
-
Hematologic Diseases / chemically induced
-
Humans
-
Infusions, Parenteral / instrumentation
-
Injections, Intravenous
-
Lung Diseases / chemically induced
-
Middle Aged
-
Mitomycins / administration & dosage
-
Neoplasm Recurrence, Local / drug therapy
-
Uterine Cervical Neoplasms / drug therapy*
Substances
-
Mitomycins
-
Bleomycin
-
Cisplatin